
News|Articles|February 6, 2006
New product newswire: February 2, 2006
The FDA gave marketing approval to ZLB Behring, King of Prussia,Pa., for an immunoglobulin (Ig) replacement therapy that can beself-administered by patients at home. Vivaglobin (immune globulinsubcutaneous [human]), indicated for treating patients with primaryimmunodeficiency, delivers antibodies subcutaneously, as analternative to intravenous infusions of immunoglobulin, to fightlife-threatening infections. The firm can be reached at (610)878-4000.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Gaps Between Expectations and Effects on Long COVID Contribute to Trust in Vaccines
2
Pharmacy Technology Should Focus on Patient Engagement, Peer Insight | NCPA 2025
3
OTC Product Roundup: Pain Relief and Symptom Management
4
How Pharmacies’ Ability to Provide Behavioral Health Services is Growing | NCPA 2025
5